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Abstract: Osteosarcomas (OSs) are bone tumors most commonly found in pediatric and adolescent
patients characterized by high risk of metastatic progression and recurrence after therapy. Effective
therapeutic management of this disease still remains elusive as evidenced by poor patient survival
rates. To achieve a more effective therapeutic management regimen, and hence patient survival,
there is a need to identify more focused targeted therapies for OSs treatment in the clinical setting.
The role of the OS tumor stroma microenvironment plays a significant part in the development and
dissemination of this disease. Important components, and hence potential targets for treatment,
are the tumor-infiltrating macrophages that are known to orchestrate many aspects of OS stromal
signaling and disease progression. In particular, increased infiltration of M2-like tumor-associated
macrophages (TAMs) has been associated with OS metastasis and poor patient prognosis despite
currently used aggressive therapies regimens. This review aims to provide a summary update of
current macrophage-centered knowledge and to discuss the possible roles that macrophages play in
the process of OS metastasis development focusing on the potential influence of stromal cross-talk
signaling between TAMs, cancer-stem cells and additional OSs tumoral microenvironment factors.
Keywords: tumor-associated macrophages (TAMs); osteosarcomas (OSs); metastasis; cancer-stem
cells; mesenchymal stem cells; tumor microenvironment; therapy
1. Introduction
Osteosarcoma (OS) is the most common type of malignant primary tumor in bone tissue, affecting
mainly children and young adults. Metastatic progression to pulmonary tissue and subsequent patient
relapse remains the leading cause of mortality in the clinical setting for OS patients [1]. Current
treatments for OS patients typically include surgery in combination with adjuvant and neo-adjuvant
chemotherapeutic agents. The survival rate for metastatic OS patients is currently estimated at less
than five years [2]. The existence of high levels of cellular heterogeneity, and the complexity of the
molecular and genetic mechanisms associated with osteosarcomagenesis makes it extremely difficult
to develop a singular therapeutic approach in the clinical setting.
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In recent years, research into the molecular cell signaling components involved in OS has led to
an interest in evaluating potential therapeutic targets to block disease progression. Communication
between OS cells and the surrounding tumor microenvironment (TME) is necessary for tumor growth
and subsequent metastases. A major influential component within the TME are tumor-associated
macrophages (TAMs) that are immune cells involved in inflammatory responses and tissue
homeostasis [3]. In most solid cancers, increased infiltration of TAMs has long been associated
with poor patient prognosis highlighting their value as potential diagnostic and prognostic biomarkers
in cancerous tissues. Recently, heterogeneous population of TAMs with an intermediate phenotype
M1–M2 have been observed in primary OS associated with anti-metastatic activity [4]. However,
a number of studies have also indicated a role for TAMs in metastatic OS. A higher density of M2-type
TAMs were found in lung metastases compared to primary OS in association with proinflammatory
molecules resulting in increased tumor invasive capability [5]. Additional studies demonstrated the
participation of TAMs in promoting angiogenesis via the activation of intracellular signaling pathways
known to be involved in cancer progression [6,7]. In addition, blocking M2-polarization was correlated
with anti-metastatic activity in OS and reduced expression of stem cell-like properties [8].
In this review, we aim to provide a current and comprehensive update about the known factors
participating in the recruitment and activation of TAMs and the mechanism by which TAMs supports
tumor metastasis in OS, focusing attention on the relationships between the signaling regulating the
cross-talk between TAMs, cancer stem-cells (CSCs) and mesenchymal stem cells (MSCs) in primary
and metastatic OS. Although anticancer therapy based on macrophage-centered approaches have been
investigated, a better understanding of the role of TAMs in OS is required to improve and develop
therapeutic strategies targeting macrophages.
2. Osteosarcoma and Macrophage Function
2.1. Osteosarcoma: Clinical and Molecular Features
Osteosarcoma is a primary malignant bone tumor mainly affecting children and young adults in
the age range between 10–20 years old [1]. With a worldwide incidence of 3/100,000, OS commonly
develops in the metaphyseal growth plates of the elongating long bones. Typical signs and symptoms
of OS are localized pain followed by localized swelling and limited joint movement, while pathologic
fracture at the site of the disease is a rare event [9]. OS is a highly metastatic cancer. OS metastasis
preferentially localizes in lung tissue with distant bones and lymph nodes as the second most common
locations sites. Metastatic disease and relapse remain the leading cause of mortality for OS patients.
Around 30% of OS patients with localized disease and around 80% with metastatic disease at diagnosis
will relapse [1]. Despite current aggressive therapy approaches, prognosis for OS patients remains
poor with less than a 30% survival rate after five years for patients presenting metastatic disease or
patients who have relapsed post treatment. In contrast, the survival rate for patients with localized OS
is around 75% [2]. Histological analysis of localized OS in bone tissue shows a measurable high-grade
neoplasm within the medullary as the most frequent indicative factor observed [10]. OS can be further
sub-classified or graded depending on the location of the neoplasm in relation to the medullary
tissue and can be defined as osteoblastic, chondroblastic and fibroblastic OS [10]. Rare variants of OS
are based on distinct intrinsic morphologic patterns including telangiectatic OS, small cell OS and
low-grade central OS. Additional classifications can be defined using the site of the disease and are
denoted as parosteal OS, periosteal OS and high-grade surface OS. These localized variants can show
distinctive clinical characteristics [11,12]. OS originates from oncogenic and epigenetic events involving
primitive mesenchymal cells (MSCs) which, once differentiated into osteoblasts, produce malignant
osteoid and immature bone tissue [13]. Most OS occurs sporadically and is characterized by high
heterogeneity both at the intra- and inter-tumoral level. OS possesses unique features compared to other
pediatric cancers, including an extremely complex genomic background with a high degree of genomic
instability and has an unusually high mutation rate and a high number of mutated driver genes [14].
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In a small percentage of patients, OS has a genetic origin. The association between the increased risk of
developing OS and several rare inherited cancers syndromes, such as Li–Fraumeni and retinoblastoma
familial cancers (germ-line mutations in TP53 and RB1, respectively) or Rothmund–Thomson, Werner
and Bloom (germline mutations in DNA helicase genes RECQL4, RECQL2 and RECQL3, respectively),
have been well documented [15]. Recently, other germ-line pathogenic variants have been detected
in genes not previously associated with OS such as CDKN2A, MEN1, VHL, POT1, APC, MSH2 and
ATRX in more than 25% of OS patients [16]. High-grade OS is characterized by widespread genomic
alterations encompassing hyperdiploidy, chromosomal re-arrangements, copy number variation and a
very high somatic mutation rate [14,17]. Recurrent mutations, in a set of cancer-related genes, have been
identified by genome-wide NGS techniques [18,19]. Alteration of onco- or tumor-suppressor genes
that are involved in signaling pathways regulating three core cellular processes: cell fate, cell survival,
and maintenance of genome stability have also been detected [19]. Loss-of-function variants have
been observed for TP53, RB1, DLG2, PTEN, CDKN2A, ATRX genes and are mainly caused by deletion,
mutation or translocation events or by copy number variations; while gain-of function variants have
been observed for MYC, CCNE1, COPS3, AURKB, CDK4, MDM2, IGF1R and AKT genes and are mainly
due to gene amplification events. Among these, TP53 and RB1 tumor suppressor genes have shown
the highest mutation frequency [20]. Loss of function mutations for these two have been reported
as the main drivers of the events resulting in the development of sporadic OS [20]. Furthermore,
mutations of several regulators of p53 and RB1 activity were also observed including amplification
of the MDM2 and CDK4 genes. A whole exome sequencing investigation uncovered mutations in
alternative driver genes, including a BRCA1/2 defect [18]. OS cells also showed alterations in their
epigenetic machinery including DNA methylation, histone modifications and ncRNAs expression [21].
Functional analysis of the differentially methylated genes revealed that these genes are mainly involved
in biologic processes related to an inflammatory/immune response involving pertussis pathways and
hematopoietic cell lineage pathways [22]. Additionally, hypomethylation of oncogenic elements have
also been observed [23,24]. Epigenetic alterations have been associated with resistance to chemotherapy
and relapsing forms of OS [25]. Aberrant expression of both onco- and tumor-suppressor genes,
generated by genetic and epigenetic events, results in uncontrolled cell-signaling pathway and cellular
processes. The PI3K/Akt pathway is universally accepted as one of the most important oncogenic
drivers in OS [26,27]. The Wnt/ β-catenin-signaling pathway is markedly upregulated in OS and plays
a pivotal role in tumorigenesis [28,29] and metastases [30]. Recently, the involvement of this pathway
in angiogenesis and immuno-surveillance has been also reported [31,32]. Increasingly data suggest
the abnormal activation of the hedgehog (Hh) pathway that has a pivotal role in signaling during
embryogenesis, in OS [33,34] and several therapeutic strategies have been developed to target this
pathway [35,36]. The prognostic and predictive impact of the expression of p16 [37], HER2 [38] and
β-catenin [39] have also been investigated with some promising results.
Tumorigenesis and cancer progression is supported by crosstalk-signaling between OS cells and
the surrounding TME, being mainly composed of stromal cells, immune cells, endothelial cells and
bone cells [40]. The immune component of OS TME is predominantly represented by the presence
of tumor-associated macrophages (TAMs) that may act to impede or enhance the development and
progression of tumor (Figure 1).






Figure 1. (a) Primary and (b; lung) metastatic osteosarcoma (OS) sections stained for CD163 
(clone 10D6 Thermo Scientific). Dense infiltration of tumor-associated macrophages 
(TAMs) is indicated by diffuse stromal reactivity of CD163 (brown) as previously described 
[41]. 
2.2. Macrophages and Bone Homeostasis 
Macrophages are a heterogeneous population of innate myeloid cells that can infiltrate all 
mammalian tissues [42] and have multiple roles in organ development, immune surveillance, 
homeostasis and tissue turnover [43]. Expressing a broad array of cell-surface receptors, intracellular 
mediators and secretory molecules, macrophages play an essential role during the inflammatory 
response and coordinate host defense mechanisms [44,45]. 
Macrophages are involved in bone homeostasis and immunity and have central functions in 
osteoimmunology [46]. Three known distinct macrophage populations have been identified in the 
bone skeletal tissue: bone marrow macrophages (erythroid island macrophages and hematopoietic 
stem cell macrophages), osteoclasts (multinucleated tissue-resident macrophages in bone) and a 
population of macrophages termed osteal macrophages or “osteomacs” [47]. The role of macrophages 
in bone biology has been characterized in vitro and in vivo. Human and murine macrophages 
produce the bone morphogenetic proteins-2 (BMP-2) and -6 (BMP-6) [48] required for mineralization 
and osteoblastic differentiation gene expression [47]. Interestingly, human macrophages-derived 
oncostatin M (OSM) enhances MSCs differentiation into osteoblasts [49,50] and matrix mineralization 
[51]. In addition, it has also been reported that the number of osteoblasts lining bone surfaces and 
bone formation capability decreases in macrophage ablation models and that osteoporosis increases 
in skeletally mature mice [52–56]. 
Macrophages possess high plasticity and can acquire opposing phenotypes: the inflammatory 
phenotype or classical (M1) and the anti-inflammatory or alternative phenotype (M2) [57–59]. 
Polarized macrophages have different functional roles in bone homeostasis. In studies, it was found 
that the expression of the osteoinductive factors BMP-2 and BMP-6 were reduced in M1-like 
macrophages in the presence of M1-conditioned medium and the differentiation of MSCs into 
osteoblasts was subsequently impaired [48]. Whereas M2-like macrophages participate in the 
efferocytosis (clearance of apoptotic cells) [60] and conditioned media from M2-like macrophages 
increased osteoblast maturation from MSCs [50], indicating that alternatively activated macrophages 
work as mediators of bone homeostasis. 
2.3. Macrophages: Origin and Plasticity 
Previous reports looking at tissue macrophage derivation, suggested that they were derived 
from circulating monocytes that differentiate into mature macrophages once they are recruited into 
tissues [61,62]. However, emerging evidence suggests that macrophages in many steady-state tissues 
are not derived from circulating monocytes as originally thought, but rather from embryonic 
macrophages that are able to self-maintain independently of the adult hematopoietic system [63–68]. 
Figure 1. (a) Primary and (b; lung) metastatic osteosarc ma (OS) sections stai ed for CD163 (clone
10D6 Thermo Scientific). Dense infiltration of tumor-associated macrophages (TAMs) is indicated by
diffuse stromal reactivity of CD163 (brown) as previously described [41].
2.2. Macrophages and Bone Homeostasis
ac ages are a heterogeneous population of innate myeloid cells that can infiltrate all
mammalian tissues [42] and have multiple roles in organ development, immune surveillance,
homeostasis and tissue turnover [43]. Expressing a broad array of cell-surface receptors, intracellular
mediators and secretory molecules, macrophages play an essential role during the inflammatory
response and coordinate host defense mechanisms [44,45].
Macrophages are involved in bone homeostasis and immunity and have central functions in
osteoimmunology [46]. Three known distinct macrophage populations have been identified in the bone
skeletal tissue: bone marrow macrophages (erythroid island macrophages and hematopoietic stem cell
macrophages), osteoclasts (multinucleated tissue-resident macrophages in bone) and a population of
macrophages termed osteal macrophages or “osteomacs” [47]. The role of macrophages in bone biology
has been characterized in vitro and in vivo. Human and murine macrophages produce the bone
morphogenetic proteins-2 (BMP-2) and -6 (BMP-6) [48] required for mineralization and osteoblastic
differentiation gene expression [47]. Interestingly, human macrophages-derived oncostatin M (OSM)
enhances MSCs differentiation into osteoblasts [49,50] and matrix mineralization [51]. In addition,
it has also been reported that the number of osteoblasts lining bone surfaces and bone formation
capability decreases in macrophage ablation models and that osteoporosis increases in skeletally
mature mice [52–56].
Macrophages possess high plasticity and can acquire opposing phenotypes: the inflammatory
phenotype or classical (M1) and the anti-inflammatory or alternative phenotype (M2) [57–59]. Polarized
macrophages have different functional roles in bone homeostasis. In studies, it was found that the
expression of the osteoinductive factors BMP-2 and BMP-6 were reduced in M1-like macrophages in the
presence of M1-conditioned medium and the differentiation of MSCs into osteoblasts was subsequently
impaired [48]. Whereas M2-like macrophages participate in the efferocytosis (clearance of apoptotic
cells) [60] and conditioned media from M2-like macrophages increased osteoblast maturation from
MSCs [50], indicating that alternatively activated macrophages work as mediators of bone homeostasis.
2.3. Macrophages: Origin and Plasticity
Previous reports looking at tissue macrophage derivation, suggested that they were derived
from circulating monocytes that differentiate into mature macrophages once they are recruited
into tissues [61,62]. However, emerging evidence suggests that macrophages in many steady-state
tissues are not derived from circulating monocytes as originally thought, but rather from embryonic
macrophages that are able to self-maintain independently of the adult hematopoietic system [63–68].
Based on more recent work it is now thought that macrophages originate from at least three different
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embryonic sources; from macrophage/dendritic cell progenitor cells (MDPs) in the bone marrow; from
erythro-myeloid progenitor (EMP) in the yolk sac and fetal liver) and differentiate into tissue-specific
macrophages; or differentiate into other cell types (such as common dendritic cell progenitors
(CDP) [69,70]. The different origin of macrophages is regulated by different regulatory mechanisms;
for example, bone-marrow derived cells require transcription factor cMYB, which is not required for
yolk-sac derived macrophages [63,71–73]. Nevertheless, regardless of their origins, colony-stimulating
factor 1 receptor (CSF1R) has been identified as the principal transmembrane receptor that controls
differentiation and survival for most macrophages [74].
Activation of macrophages is usually initiated via responses to stimuli present in their immediate
surrounding microenvironment [57,75,76]. They possess high plasticity and, according to signals
derived from the microenvironment, macrophages can adopt different functional phenotypes during
the different phases of an inflammatory reaction [57]. Classical activation, by Toll-like receptors and
interferon-γ (IFNγ), gives rise to M1 macrophages that play key roles in the hosts defense against
infections, tumor suppression and immune system stimulation. In addition, M1 macrophages are
characterized by the production of inducible nitric-oxide synthase (iNOS) and the expression of
cytokines involved in the induction of T helper type-1 (Th1) cell development, T-cell trafficking as well
as chemo-attractants [77]. On the other hand, alternative activation—by interleukins-4 or -13—induces
M2 macrophages that are involved in immune suppression, tumor angiogenesis, tissue remodeling
and tumor progression [78,79]. However, it is becoming clear that M1 and M2 classification is possibly
an oversimplification of the complexity of macrophage-polarization. In fact, due in part to their
plasticity, macrophages exist in different functional states and can be re-directed from one phenotype
to another by microenvironmental changes. In particular, M2 macrophages consist of a spectrum
of phenotypes identified as M2a, M2b, M2c and M2d [80,81], and the original two designations are
currently referred to as ‘M1-like’ and ‘M2-like’, due to the overlap of the expression of markers. TME
induces the M2-polarization of tumor-associated macrophages (TAMs) and a high M2/M1 ratio is
clinically associated with poor prognosis in many types of cancers [82].
Tumor-associated macrophages are important components of the tumor stroma and are intimately
involved in many phases of tumor growth. In several cases, macrophages can comprise up to 50% of the
tumor mass and their abundance is associated with a poor clinical outcome. A great deal of evidence
has demonstrated that TAMs promote tumor growth by facilitating angiogenesis, immunosuppression
and chronic inflammation and can also influence tumor resistance after conventional anticancer
therapies [59]. As mentioned earlier, it has been previously hypothesized that TAMs originate
from circulating monocytes. However, new evidence suggests that, while monocyte-derived TAMs
are continuously replenished by peripheral recruitment, a proportion of TAMs can also arise from
tissue-resident macrophages that are locally maintained through in situ proliferation [83,84]. TAMs play
three distinct roles in promoting tumor growth and metastases: first; TAMs facilitate the intravasation
of tumor cells into the vasculature via a paracrine-signaling loop consisting of macrophages CSF-1
from the tumor cells and EGF from macrophages and their receptors [85,86], thereby promoting
tumor dissemination [87]. Indeed, VEGF-A-expressing and Tie2-expressing macrophages produce
highly localized vascular permeability thereby facilitating the extravasation of the tumor cells [88,89];
second, TAMs promote tumor growth by inhibiting both adaptive and innate antitumor immunity by
secreting immunosuppressive molecules including TGFβ, IL10, arginase-1 (Arg-1) and NO [90–93];
third, TAMs are proangiogenic, thereby promoting tumor growth and recovery from cancer therapy.
Notably, it has been found that VEGF-A-expressing and Tie2-expressing macrophages play a crucial
role in the recovery of the tumor vasculature and the recurrence of tumor following treatment with
doxorubicin [94,95].
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3. TAMs and TME in OS
3.1. TAMs and OS Metastasis
Initial findings, providing evidence of TAMs in OS, showed that neoplastic tissue was being
infiltrated with heterogeneous populations of TAMs with M1 and M2 phenotypes [4]. Gene profiling
analysis of nonmetastatic OS samples revealed a high expression of macrophage-associated genes and
a high number of macrophages responders to chemotherapy treatment [4]. Despite the introduction
of neoadjuvant chemotherapy increasing the overall survival of OS patients, the progression to OS
metastasis has still not been overcome in the clinic. Liang et al. showed that neoadjuvant chemotherapy
induced severe local inflammation responses in OS patients resulting in chemotherapy-induced
infiltrating macrophages to release interleukin-1-beta (IL-1β) and subsequent activation of the TNF,
NF-kB and MAPKs pathways. Indeed, the binding of IL-1β to its receptor, on the OS cells, resulted
in reduced sensitivity to neoadjuvant chemotherapy [96]. Previous research findings demonstrated
the presence of reduced tumor infiltrating T cells (Tis) correlated with the persistence of M2-type
TAMs in OS tumors. Furthermore, the depletion of M2-types restored T cell proliferation and T cell
secretion of TNF-α and INF-β. Interestingly, the levels of CD163+ TAMs were higher in the tumor
stroma compared with the frequency of circulating monocytes in peripheral blood, suggesting that the
regulation of the T cell response in OS is not a systemic condition, but related to factors in TME [97].
With regard to the role of TAMs in the metastatic process, Dumars et al. showed high levels
of CD146+ vascular cells in metastatic OS samples correlating with the presence of CD163+ TAMs,
compared with nonmetastatic cells, suggesting a role for M2-types in the promotion of the neoangiogenic
process and thereby enhancing the metastatic potential of OS cells [6]. In vitro and in vivo studies
showed that metastatic OS tissues overexpress IL-34 that is involved in monocyte differentiation and
inflammation. When OS cells were stimulated with the proinflammatory cytokines, TNF-α and IL-1β,
a higher expression of IL-34 was reported [7]. Additionally, IL-34 was found to promote vasculogenesis
and OS growth via activation of signaling pathways in endothelial cells including Src, FAK and MAPKs,
known to be involved in angiogenesis and vascular homeostasis. Moreover, in vivo data showed
increases in the numbers of M2-macrophages in IL-34 expressing tissues [7]. IL-34 strongly induced
the adhesion of monocytes to endothelial cells thereby enhancing the extravasation capability of TAMs
in OS [7]. Su Y et al. also reported overexpression of CCL18, a common chemokine released by
M2-macrophages, in OS tissues. CCL18 expression was correlated with proliferation and invasion of
OS cells. Additionally, the number of CCL18+ TAMs identified was higher in metastatic OS tissues
compared with primary OS. Studies in xenograft models indicated that CCL18 increased the tumor
size and induced lung metastasis, indicating that TAMs, by secreting CCL18 promote metastasis and
tumor growth in OS [98]. Higher densities of TAMs in metastatic OS tissues has been recently recorded
correlating with a marked increase in the expression levels of COX2 and p-STAT3 (Table 1).
Table 1. Biomarkers associated with tumor-associated macrophages in OS.
Biomarkers Function Ref.
MMP-9 Matrix metalloproteinase [5]
COX2 Proinflammatory enzyme [5]
STAT3 Transcription factor [5]
CD163 Scavenger receptor hemoglobulin [6]
CCL18 Chemokine [98]





CD206 Mannose receptor [102]
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While the inhibition of COX2 reduced the migratory ability of OS cells, COX2 overexpression in OS
cells co-cultured with TAMs increased expression levels of p-STAT3 and thus the metastatic potential
of OS cells [5]. The pro-metastatic role of TAMs has already been proposed by Zhou et al. reporting
that treatment with all-trans retinoic acid (ATRA) not only prevented M2-polarization, but also showed
anti-metastatic activity in OS by blocking TAM-induced MMP12 secretion [8]. Moreover, Shao X et
al. observed a higher percentage of CD209+ M2-TAMs in primary OS. Additionally, inhibition by
ATRA reduced tumorigenesis in OS by blocking M2-polarization and, more interestingly, suppressed
the stem-like properties of OS cells such as the colony formation capability, reduced the number of
CD117+/Stro-1+ cells and the expression of stemness genes [99].
3.2. Crosstalk between TAMs, CSCs and MSCs in OS
Several tumors, including breast, lung and colorectal cancers, have been found to contain stem-like
cell populations termed cancer stem cells (CSCs), with capabilities for tumorigenesis, metastasis
and drug resistance [103]. CSCs express high levels of drug transporters and high capability for
DNA repair making them more able to resist conventional chemotherapy [104]. In OS, high levels
of the detoxifying enzyme aldehyde dehydrogenase-1 (ALDH1) have been associated with drug
resistance in stem-like populations [105]. Studies have identified increased levels of stem-like cell
gene expression and activation, notably OCT3/4, SOX4 and NANOG, identified in a small fraction of
CD133+ cells in primary human OS [106]. Tumor-initiating cells (TICs) with stem-like properties have
been further identified using the mesenchymal markers CD117 and Stro-1 in human and mouse OS
with increased metastatic and drug resistant capabilities [107]. The mesenchymal origin of the tumor
and the high expression of mesenchymal markers suggest mesenchymal stem cells (MSCs) as one of
the cells-of-origin involved in osteosarcomagenesis [108].
In OS, MSCs are recruited from bone marrow (BM) and, in response to genetic/epigenetic changes
and/or micro-environmental signals, differentiate or aberrantly differentiate [109]. Brune et al. identified
a subpopulation of OS-MSCs that share molecular and phenotypic characteristics with BM-MSCs,
supporting the hypothesis that tumor stromal MSCs can originate from BM-MSCs [110]. Malignant
transformation of mouse BM-MSCs was also observed in presence of mutated TP53 and CDKN2A
genes [111]. Moreover, TP53-deficient MSCs have been reported as being associated with an increased
expression of markers promoting tumorogenesis, immune suppression, drug resistance and metastasis
in tumor microenvironment involving CCL5, TGF-β and IL-6/STAT3 [20]. However, the incidence of
OS is higher when the alteration of cell-cycle regulators occurs in osteoblast progenitors rather than
immature MSCs, suggesting that OS cells-of-origin may be both osteoblast differentiating committed
cells and early mesenchymal progenitors, being orchestrated via signals in the tumor microenvironment
and/or as a direct response to genetic/epigenetic alterations within the cells-of-origin [108]. Le Nail et
al. reported that the injection of OS-derived cells alone was not sufficient to induce tumor initiation in
mouse model, while the co-injection of MSCs increased the metastatic potential of OS cells, suggesting
the supporting role of MSCs in tumor progression [112]. Many studies have demonstrated that MSCs
promote the metastatic potential of tumor cells by enhancing their ‘invasiveness’ as well as their ability
to create metastatic niches [113–116]. MSCs, under TME stimulation, may acquire a ‘cancer-associated
fibroblast’ (CAF) phenotype with strong invasive and migratory capabilities within the TME [117].
In addition, overexpression of IL-6 from MSCs has been correlated with the enhanced expression
of ICAM-I in tumor stromal cells resulting in the invasive potential of cancer cells to increase [109].
Additional studies have demonstrated the protective role of MSCs from the effects of anticancer
treatments in OS [109,118].
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In the tumor niche, CSCs communicate with the surrounding stromal components, including
immune cells that provide signals supporting the development of the CSCs phenotype and as a
result increases the malignant behavior of the tumor. A correlation between TAMs and CSCs has
been previously demonstrated in several tumors. TAMs secrete factors promoting the inflammatory
response and supporting stem-like phenotype of CSCs [119]. Several molecules have been identified as
mediators in crosstalk CSCs–TAMs-signaling, where TAMs were found to induce EGF/STAT3-signaling
in breast tumors [120], IL-10/JAK1-signaling in non-small lung cancer cells [121] and TGF-β1 in
hepatocellular carcinoma [122]. Inhibiting TAMs resulted in a decreased number of tumor initiating
cells and increased the chemoresistance response in pancreatic tumors [123]. More recently, it has
been suggested that the involvement of M2-TAMs, in tumor initiation, acts by inducing the stem-like
phenotype of the cancer stem cell in OS [99]. However, the TAMs-CSCs crosslink in OS remains to be
fully understood.
The paracrine communication between TAMs, MSCs and CSCs in TME plays a key role in
supporting the stem-cell niche and tumor development [113]. In this regard, Jia XH et al. reported
that MSCs promoted differentiation of macrophages toward M2 phenotype in the tumor via IL-6
secretion [100]. In multiple myeloma, a bidirectional signaling between macrophages and MSCs
was reported. Studies have shown that MSCs stimulate the differentiation of macrophages in
favor of tumor-supportive phenotypes and that the macrophages in turn promote the pro-tumor
activity of MSCs [124]. Another study reported “two-loop signaling” in breast cancer, referring to the
interplay between breast cancer cells, that recruit MSCs before the MSCs in turn recruit TAMs via
chemokine-signaling [125].
3.3. Extracellular Vesicles in OS
Several studies have reported and described the presence of extracellular vesicles (EVs) in the OS
microenvironment and their involvement in angiogenesis, tumor progression, immune escape and drug
resistance [126]. EVs are small lipid-membrane vesicles released from both normal and tumor cells in
the extracellular matrix (ECM) containing proteins, lipids and small nucleic acids able to influence the
biologic behaviors of target cells [127]. Cargo including matrix metalloproteinases-1 and -13 (MMP-1,
-13), TGF-β, CD-9 and RANKL have been detected in OS-derived EVs [128]. EVs containing TGF-β are
able to induce the IL-6-signaling pathway in MSCs (Figure 2), favoring the differentiation into the cancer
phenotype [126]. In addition, an immunosuppressive function has been also proposed for OS-derived
EVs [129]. Raimondi L. et al. observed that EVs within the OS TME increased the expression of VEGF,
IL-8, IL-6 and miRNAs supporting vasculogenesis and tumor dissemination [130]. Tumor-derived
EVs have also been reported to participate the development of multidrug resistance phenotypes with
regard to sensitive OS cells [131]. Yan B. et al. reported that exosomes secreted by TAMs induced
proliferation and invasion of cancer cells and promoted the drug-resistance phenotype by activating
the PI3K-AKT-signaling pathways in the OS cells [132] (Figure 2). A recent study reported that the
presence of alveolar macrophages in TME induces the secretion of OS-derived EVs [101]. Moreover,
they reported that EVs secreted by metastatic OS increased the expression of M2-type markers such as
TGFB2, IL10 and CCL22, reducing the phagocytic capability of alveolar macrophages [101]. Although
further evaluations are needed to assess the role of TAM-EVs in OS progression, these data identify
tumor-associated EVs as potential biomarkers for OS diagnosis which could lead to the development
of promising molecular targeted therapies for the effective treatment of OS patients.
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such as activation of signaling pathways or exchange of extracellular vesicles (EVs), makes the tumor 
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Figure 2. Role of TAMs in OS progression. Crosstalk between OS and stromal cells—via mechanisms
such as activation of signaling pathways or exchange of extracellular vesicles (EVs), makes the tumor
microenvironment (TME) conducive for cancer growth. In this regard, OS cells, by releasing TGF-β or
EVs-delivered, support the malignant phenotype of the MSCs that in turn secrete cytokines such as
IL-6 and VEGF molecules involved in promoting angiogenesis and metastasis [133]. A heterogeneous
population of TAMs, with both M1 and M2 phenotypes, infiltrates the OS tumor [4]. M2-like TAMs
play a key role in tumor progression and metastasis [133]. In particular, M2-like TAMs, by releasing
IL-1β, induce chemoresistance in primary OS cells [96]. In response to the inflammatory stimuli,
OS cells over express IL-34 that induces M2-like TAM recruit ent, vasculogenesis and OS growth [7].
M2 macrophages are also involved in the maintenance of the stem-like phenotype of CSCs [99].
However, the exact mechanism by which TAMs and CSCs communicate in OS remains to be fully
investigated, together with the possibility of a bidirectional link between TAMs and MSCs, as observed
in other tumor types [124,125]. High numbers of TAMs in the TME are associated with metastatic
OS tissue and poor survival rates for OS patients [134]. TAMs support tumor invasiveness via the
secretion of CCL18 [98], proinflammatory molecules such as COX2 that, in turn, activate the IL-6/STAT3
pathway in OS cells and MMP-9, increasing th metastatic potential of the tumor [5]. OS-derived EVs
have been shown to increase the expression of M2-type markers such as TGFB , IL-10 and CCL22 in
lung OS metastasis [101]. I addition, it has also been r ported that proliferative TAMs support cancer
metastasis process [135].
4. TAM and OS Therapy
Current OS treatment consists of neoadjuvant multidrug chemotherapy comprising cisplatin,
doxorubicin, methotrexate (MAP therapy) and Ifosfamide, followed by surgery and postoperative
chemotherapy [136]. Radiotherapy is also included used to prevent the growth of the tumor located
in high risk areas and as palliative treatment for bone pain in pediatric patients [137]. A five years
overall survival rate can be estimated for patients with primary OS by following the aforementioned
therapeutic approaches; however, poor therapy response and no improvements in the outcome in
patients with metastatic OS has been reported for many years in the clinical setting [136].
Post-surgery histological evaluation has long been used as prognostic tool for OS outcome.
Nowadays, new prognostic molecular biomarkers are available, including single nucleotide
polymorphism, microRNAs and epigenetic factors that have been useful in identifying the tumor
stage, tumor behaviors and the specific therapeutic approach needed to improve the clinical outcome
of OS patients [136]. Recently, tumor inflammation was also considered as a prognostic tool for OS,
given that stromal inflammation has been correlated with poor prognosis, tu or aggressiveness and
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metastasis. The use of anti-inflammatory drugs in combination with chemotherapy has also been
reported and appears to have a direct effect on increasing patient survival rates [138].
TAMs as a Target in OS Therapy
Evidence indicates that the ratio of M1 to M2 macrophages may regulate the potential for OSs to
metastasize by changing the TME to one that is conducive for metastasis to occur [139]. Therefore, by
targeting strategies that modulate TAM-polarization from an M2 phenotype to an M1 phenotype may
have a beneficial result in minimizing the effects seen during macrophage aided tumor progression.
Clinical trials have shown that when the liposome-encapsulated muramyl tripeptide mifamurtide
(a macrophage activating agent) was used, in combination with standard chemotherapy regimens,
resulted in an increase of the 6-year survival rates in OS patients [140–142]. In phase II clinical trials
mifamurtide induced the infiltration of activated macrophages into OS lung tissue metastases [143] with
a marked difference in disease progression and overall survival [144] and that the mifamurtide-mediated
M1-TAMs antitumor activity required IFN-γ [145]. Punzo et al. demonstrated that, by switching
macrophage polarization towards a TAM-like intermediate M1/M2 phenotype, mifamurtide may
work by modulating macrophage functions and inhibit OS proliferation [102]. In order to enhance
the activation of the immune response, the European Medical Agency (EMA) has approved the
use of mifamurtide, as an adjuvant in combination with chemotherapy, for the treatment of OS
patients [146]. In pre-clinical models of OS, the prevalence of M2-type TAMs was correlated with an
increase in tumor progression, angiogenesis and metastatic dissemination [6–8,147]. It is currently
thought that M2-like TAMs, may be suitable targets for anti-metastatic therapy in treating OS patients
(Table 2). Recent evidence has demonstrated that All Trans retinoic acid (ATRA) suppresses tumor
metastases [148,149], reduces the polarization and infiltration of M2-like TAM cells in the TME and
may abrogate pulmonary OS metastasis [8]. M2-like TAM-polarization may also be influenced by the
action of the dihydroxycoumarins esculetin and daphnetin, acting via regulation of pSTAT3 and IL-10
that may inhibit the differentiation of M2-types and have reductive effect on OS metastasis in vitro and
in vivo [150].
zoledronate (a nitrogen-containing bisphosphonate) also modulates TAM-polarization from
M2 to M1 phenotypes [151]. It has also been reported that the TAM functions are affected by
bisphosphonates [152]. Drugs such as clodronate and zoledronate are anti-resorptive drugs that have
direct effects on osteoclasts and can interrupt the vicious cycle between osteoclasts and bone cancer
cells as well as significantly diminishing OS-induced lung metastasis in vivo [153–155].
Another approach used in several in vivo research models investigating common types of cancers,
is the use of macrophages depletion techniques [156]. Recently, Zhou Q. et al. reported that in clodronate
liposome (CLO-LIP) treated mice, M2-like TAMs were actively depleted, and the incidence of lung OS
metastasis was markedly reduced [8].
Several studies have shown the importance of macrophage and cancer cell interaction for the
intravasation and invasion at distant sites [86,157]. The crosstalk between VCAM1 receptor on the
tumor cell surface and α4 monocytes integrins has been shown to be an important factor in several
in vivo mouse tumor models [157]. Treatment with natalizumab, a monoclonal antibody against
the α4 integrin, has been shown to decrease tumor growth in mouse bone marrow [157]. Currently,
natalizumab is in clinical trials for OS (ClinicalTrials.gov Identifier: NCT03811886). Targeting agents
that interfere with the signaling crosstalk between cancer cells and TAMs, such as via VCAM-1/α4
integrin, could be an attractive approach to developing novel therapies for more effective OS treatments
and improved patient survival rates in the clinical setting.
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Table 2. Therapeutic agents targeting TAMs for OS treatment.
Agent Mechanism Phase Ref.









Zoledronate Polarizes TAMs to M1-like 3 [151]
Natalizumab Interferes cross-talk betweencancer cells and TAMs NCT03811886 [157]
Nivolumab mAbs anti-PD-1 NCT02304458 [158]
Pembrolizumab mAbs anti-PD-1 NCT02301039 [158]
In addition, it has been reported that program death ligand-1 (PDL-1) and PDL-2 were detectable
in human OS cells and OS patient lung metastases [159–164]. By targeting the immune checkpoint
PD-1/PD-L1-signaling pathway, researchers have reported a reduction in tumor growth and an increase
in T-cell immune responses in OS mouse models, indicating possible application as therapeutic targets
for future OS treatment [165]. Anti-PD1 antibody led to increased numbers of antitumor M1-like TAMs
that correlated closely with reduced M2-like TAM numbers providing a novel mechanism for PD-1
blockade [158]. Clinical trials are currently underway involving the use and evaluation of nivolumab
and pembrolizumab (anti-PD1 mAbs) as therapeutic treatments in pediatric OS patients [134]. However,
there is still a great deal of research work needed in order to develop effective and targeted therapies
for successful OS treatments outcomes in the clinic.
5. Future Perspectives
As in many solid tumors, macrophages represent the main immune component in the
OS micro-environment and therapies that focus on targeting TAMs have become a hot topic
in immunotherapy. Currently macrophage-centered therapy includes elimination of TAMs and
re-polarization of TAMs into proinflammatory M1-type macrophages. Although the clinically beneficial
for OS patients and effective therapy development has improved in recent years, the use of drugs that
can change the M1/M2 ratio in favor of M1 (e.g., mifamurtide) require additional investigation [146].
In summary, the identification of new molecular targets, capable of regulating the polarization
and recruitment of TAMs, is required if we are to improve the effectiveness of current OS therapies.
Recently, it has been observed that macrophage PI 3-kinase γ [166], ERK5-MAPK [41] and cMaf [167]
promote M2-like macrophage-polarization and control the switch between immune stimulation
and suppression in cancer. Indeed, by blocking some of these signaling pathways it is possible to
redirects TAM-polarization in favor of an M1 proinflammatory phenotype with both antitumor
and anti-metastatic effects. Recently developed nanoparticle-based therapies provide potential
platforms for tumor therapy advancement [168,169]. The use of nanoparticles loaded with specific
intracellular-signaling molecular inhibitors, such as PI 3-kinase γ inhibitor [170], to change the TAM
phenotype could be a promising alternative for the direct targeting of TAM therapy in OS.
It has been also been reported that cytotoxic CD8+ T lymphocytes are less abundant than myeloid
cells in OS biopsies, suggesting that OSs are poorly immunogenic tumors [171,172]. Additional studies
looking at the use of a chimeric antigen receptor (CAR) T cell therapy resulted in the development
of CAR macrophages CAR-Ms [173]. CAR-Ms were shown to express proinflammatory cytokines and
chemokines and were also noted to be effective in converting by stander M2 into M1 macrophages that
demonstrated antigen-specific phagocytosis. Notably, a single infusion of human CAR-Ms decreased the
tumor burden and prolonged overall survival in using a xenograft mouse model. In a humanized immune
system (HIS) mouse model CAR-Ms were further shown to induce a proinflammatory TME response and
to boost antitumor T cell activity. CAR macrophages are known to kill tumors both in human samples
and in mouse models [173]. With genetically engineered macrophages, it may prove possible to directly
influence the effectiveness of current combined therapies that are in use in OS patients beneficially.
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